Wound healing involves more than closing a visible gap. Tissue integrity, infection, recurrence and function can all matter. A peptide study should be assessed against the specific wound and endpoint it actually examined.

A randomized study investigated topical full-length thymosin beta-4 in patients with venous ulcers. That is a defined human trial involving a particular formulation and condition. It is not evidence for every product marketed under a related peptide name. Randomized thymosin beta 4 trial in venous ulcers

Full-length peptides and fragments are not interchangeable

FDA’s safety discussion identifies a thymosin beta-4 fragment associated with the name TB-500. Evidence for a full-length molecule should not be silently assigned to a fragment, nor should results for a topical formulation be converted into an injectable treatment claim. FDA safety concerns for nominated compounding substances

The same principle applies across wound types. A venous ulcer differs from a surgical incision, burn or tendon injury. The underlying cause and standard care affect the interpretation of an apparent treatment effect.

Read the endpoint and the control treatment

Ask whether the study measured complete closure, time to closure, wound area or a biological marker. Check what background wound care both groups received and whether assessments were blinded. A smaller wound at one visit is not necessarily proof of durable healing.

Preclinical experiments can help explain possible mechanisms, but they do not replace appropriate human trials. A pathway associated with cell migration or collagen is only part of a much larger clinical question.

AXON’s conclusion is that wound-healing research should be molecule-, formulation- and condition-specific. The sources reviewed here do not justify a general peptide healing protocol, and a research product should not be used to delay proper assessment of a wound or its underlying cause.